International Clinical Trial: A randomized, double-blind, single dose, parallel group, three-arm comparative study assessing pharmacokinetics, safety, tolerability, and immunogenicity in healthy adult human participants

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (CTRI/2026/09/117298) titled 'A randomized, double-blind, single dose, parallel group, three-arm comparative study assessing pharmacokinetics, safety, tolerability, and immunogenicity in healthy adult human participants' on Sept. 9.

Study Type: BA/BE

Study Design: Randomized, Parallel Group, Multiple Arm Trial Method of generating randomization sequence:Stratified randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

Primary Sponsor: Cipla Ltd

Intervention: Intervention1: ASP100 Dupilumab 300mg per 2ml: A proposed biosimilar to Dupixent 300mg per 2ml...